3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Breast
1
Conditions
Breast Neoplasms
28
Pancreatic Neoplasms
8
Triple Negative Breast Neoplasms
7
Colorectal Neoplasms
7
Carcinoma, Non-Small-Cell Lung
6
Stomach Neoplasms
5
Neoplasms
5
Neoplasm Metastasis
5
Small Cell Lung Carcinoma
4
Ovarian Neoplasms
4
Breast Neoplasms, Male
4
Sarcoma
3
Rectal Neoplasms
3
Prostatic Neoplasms
3
Lung Neoplasms
3
Head and Neck Neoplasms
3
Colonic Neoplasms
3
Kidney Neoplasms
2
Gallbladder Neoplasms
2
Esophageal Neoplasms
2
Carcinoma, Renal Cell
2
Carcinoma, Hepatocellular
2
Breast Cancer Metastatic
2
Brain Neoplasms
2
Bile Duct Neoplasms
2
Appendiceal Neoplasms
2
Anus Neoplasms
2
Uterine Cervical Neoplasms
1
Urinary Bladder Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Interventions
Trastuzumab
5
Carboplatin
5
Docetaxel
4
pertuzumab
3
Paclitaxel
3
Cyclophosphamide
3
pembrolizumab
2
Epirubicin
2
Doxorubicin
2
zanidatamab
1
veliparib
1
tucatinib
1
trilaciclib
1
trebananib
1
trastuzumab duocarmazine
1
taxane
1
talazoparib
1
sarilumab
1
pyrotinib
1
pirarubicin
1
pexidartinib
1
patritumab
1
olaparib
1
niraparib
1
neratinib
1
ganitumab
1
durvalumab
1
dostarlimab
1
cemiplimab
1
abemaciclib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Pathologic Complete Response
×
Irinotecan
×
Breast
×
Clear all
NCT01042379
2026-05-06
I-SPY
QuantumLeap Healthcare Collaborative
Phase 2
Recruiting
5,000 enrolled